Thomas Jensen
Fondateur chez ALLARITY THERAPEUTICS, INC.
Fortune : - $ au 30/06/2024
Profil
Thomas H.
Jensen is the founder of Medical Prognosis Institute A (founded in 2006), XRGenomics Ltd.
(founded in 2012), Allarity Therapeutics A (founded in 2004), and Allarity Therapeutics, Inc. (founded in 2020).
He currently holds the position of Director at Cardeon AB.
Previously, he served as the Chief Technology Officer at Oncology Venture Sweden AB.
Mr. Jensen obtained his undergraduate degree from the Technical University of Denmark.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/06/2024 | 1 ( 0,00% ) | 0 $ | 30/06/2024 |
Postes actifs de Thomas Jensen
| Sociétés | Poste | Début |
|---|---|---|
| ALLARITY THERAPEUTICS, INC. | Fondateur | 06/04/2021 |
| CARDEON AB | Directeur/Membre du Conseil | - |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Fondateur | 01/01/2004 |
Anciens postes connus de Thomas Jensen
| Sociétés | Poste | Fin |
|---|---|---|
Medical Prognosis Institute A/S
 Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Fondateur | - |
| XRGenomics Ltd. | Fondateur | - |
Oncology Venture Sweden AB
 Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Directeur Technique/Scientifique/R&D | - |
Formation de Thomas Jensen
| Technical University of Denmark | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALLARITY THERAPEUTICS, INC. | Health Technology |
| CARDEON AB | Finance |
| Entreprise privées | 4 |
|---|---|
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
| XRGenomics Ltd. | |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
